دورية أكاديمية
أعرض في EDS

Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease.

التفاصيل البيبلوغرافية
العنوان: Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease.
المؤلفون: Welty FK; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA., Hariri E; Cleveland Clinic Foundation Cleveland Ohio USA., Asbeutah AA; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA., Daher R; Gilbert and Rose-Marie Chagoury School of Medicine Lebanese American University Byblos Lebanon., Amangurbanova M; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA., Chedid G; Gilbert and Rose-Marie Chagoury School of Medicine Lebanese American University Byblos Lebanon., Elajami TK; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA., Alfaddagh A; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA., Malik A; Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA.
المصدر: Journal of the American Heart Association [J Am Heart Assoc] 2023 Sep 19; Vol. 12 (18), pp. e030071. Date of Electronic Publication: 2023 Sep 08.
نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Wiley-Blackwell
مواضيع طبية MeSH: Coronary Artery Disease*/diagnostic imaging, Humans ; Middle Aged ; Aged ; Blood Pressure ; Docosahexaenoic Acids ; Eicosapentaenoic Acid/therapeutic use ; Cholesterol, LDL ; Inflammation ; Plaque, Amyloid ; Triglycerides
مستخلص: Background Residual risk of cardiovascular events and plaque progression remains despite reduction in low-density lipoprotein cholesterol. Factors contributing to residual risk remain unclear. The authors examined the role of eicosapentaenoic acid and docosahexaenoic acid in coronary plaque regression and its predictors. Methods and Results A total of 240 patients with stable coronary artery disease were randomized to eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) or none for 30 months. Patients were stratified by regression or progression of coronary fatty plaque measured by coronary computed tomographic angiography. Cardiac events were ascertained. The mean±SD age was 63.0±7.7 years, mean low-density lipoprotein cholesterol level was <2.07 mmol/L, and median triglyceride level was <1.38 mmol/L. Regressors had a 14.9% reduction in triglycerides that correlated with fatty plaque regression ( r =0.135; P =0.036). Compared with regressors, progressors had higher cardiac events (5% vs 22.3%, respectively; P <0.001) and a 2.89-fold increased risk of cardiac events (95% CI, 1.1-8.0; P =0.034). Baseline non-high-density lipoprotein cholesterol level <2.59 mmol/L (100 mg/dL) and systolic blood pressure <125 mm Hg were significant independent predictors of fatty plaque regression. Normotensive patients taking eicosapentaenoic acid plus docosahexaenoic acid had regression of noncalcified coronary plaque that correlated with triglyceride reduction ( r =0.35; P =0.034) and a significant decrease in neutrophil/lymphocyte ratio. In contrast, hypertensive patients had no change in noncalcified coronary plaque or neutrophil/lymphocyte ratio. Conclusions Triglyceride reduction, systolic blood pressure <125 mm Hg, and non-high-density lipoprotein cholesterol <2.59 mmol/L were associated with coronary plaque regression and reduced cardiac events. Normotensive patients had greater benefit than hypertensive patients potentially due to lower levels of inflammation. Future studies should examine the role of inflammation in plaque regression. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624727.
References: J Am Heart Assoc. 2017 Jul 14;6(7):. (PMID: 28710178)
J Clin Med. 2020 Aug 26;9(9):. (PMID: 32858869)
Eur J Epidemiol. 2019 May;34(5):463-470. (PMID: 30569368)
J Cardiovasc Comput Tomogr. 2011 Jan-Feb;5(1):35-43. (PMID: 21131252)
Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2220-2228. (PMID: 27515380)
Bratisl Lek Listy. 2021;122(7):474-488. (PMID: 34161115)
Invest Radiol. 2007 Mar;42(3):189-95. (PMID: 17287649)
Arterioscler Thromb Vasc Biol. 2023 Feb;43(2):382-384. (PMID: 36579646)
Biomed Res Int. 2018 Nov 11;2018:2703518. (PMID: 30534554)
JACC Cardiovasc Imaging. 2011 May;4(5):537-48. (PMID: 21565743)
Circulation. 2019 Jun 18;139(25):e1082-e1143. (PMID: 30586774)
Atherosclerosis. 2004 Jan;172(1):1-6. (PMID: 14709350)
JAMA. 2009 Nov 11;302(18):1993-2000. (PMID: 19903920)
Eur Radiol. 2010 Dec;20(12):2824-33. (PMID: 20640900)
Am J Clin Nutr. 2021 May 8;113(5):1168-1176. (PMID: 33675344)
J Cardiovasc Comput Tomogr. 2016 Mar-Apr;10(2):97-104. (PMID: 26837235)
J Am Coll Cardiol. 2010 Jun 15;55(24):2736-42. (PMID: 20538166)
Circ Cardiovasc Imaging. 2015 Jul;8(7):e003316. (PMID: 26156016)
Tex Heart Inst J. 2013;40(1):17-29. (PMID: 23467296)
Eur J Immunol. 1975 May;5(5):337-43. (PMID: 1086235)
Atherosclerosis. 2019 Jun;285:153-162. (PMID: 31055222)
Curr Atheroscler Rep. 2012 Feb;14(1):1-10. (PMID: 22102062)
Am J Cardiovasc Dis. 2012;2(2):84-8. (PMID: 22720196)
JAMA. 1998 May 13;279(18):1477-82. (PMID: 9600484)
Arch Intern Med. 2001 Jun 11;161(11):1413-9. (PMID: 11386890)
J Clin Lipidol. 2018 Jul - Aug;12(4):937-947.e2. (PMID: 29752179)
J Atheroscler Thromb. 2005;12(2):67-72. (PMID: 15942115)
N Engl J Med. 2004 Apr 1;350(14):1387-97. (PMID: 15070788)
Cardiovasc Res. 1999 Feb;41(2):334-44. (PMID: 10341833)
Expert Rev Cardiovasc Ther. 2013 Jan;11(1):55-9. (PMID: 23259445)
Nephron. 2015;130(4):263-70. (PMID: 26182958)
J Am Heart Assoc. 2017 Dec 15;6(12):. (PMID: 29246960)
JACC Cardiovasc Imaging. 2010 Jul;3(7):691-8. (PMID: 20633846)
JAMA Cardiol. 2016 Jul 1;1(4):413-23. (PMID: 27438317)
J Am Coll Cardiol. 2009 Jun 30;54(1):49-57. (PMID: 19555840)
Atherosclerosis. 2018 Oct;277:34-41. (PMID: 30170222)
J Am Coll Cardiol. 2013 Jun 4;61(22):2296-305. (PMID: 23562925)
PLoS One. 2012;7(10):e46561. (PMID: 23049706)
Atherosclerosis. 2013 Feb;226(2):428-32. (PMID: 23287639)
Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356)
FASEB J. 2021 Apr;35(4):e21448. (PMID: 33749913)
Circulation. 2004 Nov 2;110(18):2824-30. (PMID: 15492318)
J Am Coll Cardiol. 2010 May 25;55(21):2399-407. (PMID: 20488313)
Circulation. 2019 Oct 15;140(16):1308-1317. (PMID: 31530008)
Circulation. 2005 Nov 29;112(22):3375-83. (PMID: 16316964)
Eur Heart J. 2012 Oct;33(20):2551-67. (PMID: 22922414)
Crit Care. 2010;14(5):R192. (PMID: 21034463)
Front Med (Lausanne). 2022 Jan 20;8:798958. (PMID: 35127755)
Br J Radiol. 2009 Oct;82(982):805-12. (PMID: 19332517)
AJR Am J Roentgenol. 2009 Mar;192(3):W84-9. (PMID: 19234244)
Atherosclerosis. 1990 Oct;84(2-3):183-8. (PMID: 2282097)
Am J Pathol. 2018 Dec;188(12):2936-2947. (PMID: 30248339)
Circ Cardiovasc Imaging. 2013 Sep;6(5):655-64. (PMID: 23960215)
J Cardiovasc Comput Tomogr. 2014 May-Jun;8(3):230-7. (PMID: 24939072)
Atherosclerosis. 2013 Dec;231(2):198-204. (PMID: 24267226)
JAMA. 2007 Aug 15;298(7):776-85. (PMID: 17699011)
N Engl J Med. 2015 Nov 26;373(22):2103-16. (PMID: 26551272)
معلومات مُعتمدة: P50 HL083813 United States HL NHLBI NIH HHS; UL1 TR001102 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: cardiovascular events; coronary computed tomographic angiography; coronary plaque regression; eicosapentaenoic acid; triglyceride
سلسلة جزيئية: ClinicalTrials.gov NCT01624727
المشرفين على المادة: 25167-62-8 (Docosahexaenoic Acids)
AAN7QOV9EA (Eicosapentaenoic Acid)
0 (Cholesterol, LDL)
0 (Triglycerides)
تواريخ الأحداث: Date Created: 20230908 Date Completed: 20230920 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10547278
DOI: 10.1161/JAHA.123.030071
PMID: 37681568
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-9980
DOI:10.1161/JAHA.123.030071